Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2007-03-27
2007-03-27
Kennedy, Sharon E. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
10231767
ABSTRACT:
A surgically implantable and sealable delivery device that upon contact of its contents via an interface window or port therein with an organ or tissue exposes a therapeutic agent to the organ or tissue surface, allowing a controlled, selective and unidirectional diffusion of the agent into the tissue or organ. The device protects adjacent organs or tissue structures from unnecessary high levels of the delivered agent. Novel methods to deliver chemotherapeutics or bioactive agents to mammalian organs or tissues through a surgically implanted device by the way of a selective and protected diffusion mechanism are disclosed as well as method to achieve the sealing properties of the device.
REFERENCES:
patent: 4309776 (1982-01-01), Berguer
patent: 4378016 (1983-03-01), Loeb
patent: 4479796 (1984-10-01), Kallok
patent: 4549529 (1985-10-01), White
patent: 4768523 (1988-09-01), Cahalan et al.
patent: 4978338 (1990-12-01), Melsky et al.
patent: 5182111 (1993-01-01), Aebischer et al.
patent: 5292362 (1994-03-01), Bass et al.
patent: 5411550 (1995-05-01), Herweck et al.
patent: 5443505 (1995-08-01), Wong et al.
patent: 5445616 (1995-08-01), Kratoska et al.
patent: 5558630 (1996-09-01), Fisher
patent: 5725493 (1998-03-01), Avery et al.
patent: 5773019 (1998-06-01), Ashton et al.
patent: 5830173 (1998-11-01), Avery et al.
patent: 5836935 (1998-11-01), Ashton et al.
patent: 5902598 (1999-05-01), Chen et al.
patent: 6001386 (1999-12-01), Ashton et al.
patent: 6217895 (2001-04-01), Guo et al.
patent: 6251090 (2001-06-01), Avery et al.
patent: 6413540 (2002-07-01), Yaacobi
patent: 6416777 (2002-07-01), Yaacobi
patent: 6726920 (2004-04-01), Theeuwes et al.
patent: 7008396 (2006-03-01), Straub
patent: 2002/0188282 (2002-12-01), Greenberg
patent: 2003/0064088 (2003-04-01), Carvalho et al.
patent: 2003/0069560 (2003-04-01), Adamis et al.
patent: 2004/0024453 (2004-02-01), Castillejos
patent: 2004/0106906 (2004-06-01), Yaacobi
Ratner et al., Biomaterials Science: An Introduction to Materials in Medicine, 1996, Academic Press, pp. 322-323.
U.S. Appl. No. 60/334,177, filed Nov. 29, 2001, Borenstein et al.
U.S. Appl. No. 60/332,200, field Nov. 21, 2001, Borenstein et al.
U.S. Appl. No. 60/332,199, filed Nov. 21, 2001, Borenstein et al.
U.S. Appl. No. 60/291,445, filed May 16, 2001, Borenstein et al.
U.S. Appl. No. 60/291,340, filed May 16, 2001, Borenstein et al.
U.S. Appl. No. 60/288,373, filed May 3, 2001, Borenstein et al.
Torres-Lugo, Madeline., et al., “Transmucosal delivery systems for calcitonin: a review”,Biomaterials, vol. 21, pp. 1191-1196 (2000).
Benes, L., et al., “Transmucosal, Oral Controlled-Release, and Transdermal Drug Adminstration in Human Subjects: A Crossover Study with Melatonin”,Journal of Pharmaceutical Sciences, vol. 86, No. 10, pp. 1115-1119 (1997).
Gebhardt, Bryan M., et al., “Collagen as a Delivery System for Hydrophobic Durg: Studies with Cyclosporine”,Journal of Ocular Pharmacology and Therapeutics, vol. 11, No. 3, pp. 319-327 (1995).
Kanpolat, Ayfer., et al., “Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical Drop and Collagen Shield Adminstration”,The CLAO Journal, vol. 20, No. 2, pp. 119-122 (1994).
Lehr, C-M., “From sticky stuff to sweet receptors—Achievements, limits and novel approaches to bioadhsion”,European Journal of Drug Metabolism and Pharmacokinetics, vol. 21, No. 2, pp. 139-148 (1996).
Rudnick, David E., et al., “The effect of Intraocular Pressure on Human and Rabbit Scleral Permeability”,IOVS, vol. 40, No. 12, pp. 3054-3058 (1999).
Olsen, Timothy W., et al., “Human Sclera: Thickness and Surface Area”,American Journal of Ophthalmology, vol. 125, No. 2, pp. 237-241 (1998).
Olsen, Timothy W., et al., “Human Scleral Permeability”,Investigative Ophthalmology&Visual Science, vol. 36, No. 9, pp. 1893-1903 (1995).
Brem, Henry., et al., “Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas”,The Lancet, vol. 345, pp. 1008-1012 (1995).
Valtonen, Simo., et al., Interstitial Chemotherapy with Carmustine-loaded Polymers for High-grade Gliomas: A Randomized Double-blind Study Clinical Study,Neurosurgery, vol. 41, No. 1, pp. 44-49 (1997).
Subach, Brian R., et al., “Morbidity and Survival after 1.3-bis(-chloroethyl)-1-Nitrosourea Wafer Implantation for Recurrent Glioblastoma: A Retrospective Case-matched cohort series”,Neurosurgery, vol. 45, No. 1, pp. 17-23 (1999).
Moriya, T., et al., “Controlling Malignant Pericardial Effusion by Intrapericardial carboplatin Adminstration in Patients with Primary Non-Small-Cell Lung Cancer”,British Journal of Cancer, vol. 83, No. 7, pp. 858-862 (2000).
Lerner-Tung, Mary B., et al., “Pharmacokinetics of intrapericardial adminstration of 5-fluorouracil”,Cancer Chemother Pharmacol, vol. 40, pp. 318-320 (1997).
Darsinos, J. TH., et al., “Distribution of lidocaine and digoxin in heart tissues and aorta following intrapericardial adminstration”,International Journal of Clinical Pharmacology, Therapy and Toxicology, vol. 31, No. 12, pp. 611-615 (1993).
Darsinos, J. T., et al., “Distribution of amiodarone in heart tissues following intrapericardial adminstration”,International Journal of Clinical Pharmacology and Therapeutics, vol. 37, No. 6, pp. 301-306 (1999).
Uchida, Y., et al., “Angiogenic therapy of acute myocardial infarction by intrapeicardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study”,American Heart Journal, vol. 36, No. 6, pp. 1182-1188 (1995).
Laham, Roger J., “Intrapericardial Administration of Basic Fibroblast Growth Factor; Myocardial and Tissue Distribution and Comparison With Intracoronary and Intravenous Administration”,Catheterization and Cardiovascular Interventions, vol. 58, pp. 375-381 (2003).
D'Hermies, Francois., et al., “Scleral and episcleral histological changes related to encircling explants in 20 eyes”,ACTA Ophthalmologica Scandinavica, vol. 77, pp. 279-285 (1999).
D'Hermies, Francois., et al., “Encapsulation of Scleral Buckling Materials”,Ophthamology, vol. 105, No. 6. (1998).
Ricci, Benedetto., et al., “Octyl 2-cyanoacrylate tissue adhesive in experimental scleral buckling”,Acta Ophthalmol. Scand., vol. 78, pp. 506-508 (2001).
Korobelnik, J. F., “Expanded Polytetrafluoroethylene Episcleral Implants Used as Encircling Scleral Buckling”,Opthalmic Res, vol. 32, pp. 110-117 (2000).
Mulvihill, Alan., et al. “Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma”,Arch Ophthalmo. vol. 121, pp. 1120-1124 (2003).
D'Hermies, F., “Alterations Anatomopathologiques Liees Au Traitement Par Cerclage Des Golbes Oculaires Atteints De Decollement De Retine”,Societe D'ecition de l'Association de'Enseignement Medical des Hopitaux de Paris. pp. 215-222 (1999).
Korobelnik, J. F. et al., “e-PTFE as Scleral Buckling Episcleral Implants: An Experimental and Histopathologic Study”,John Wiley&Sons, Inc. J Biomed Mater Resvol. 48, pp. 807-813 (1999).
D'Hermies, F. et al., “Experimental Encircling Scleral Buckle With Silicone and Hydrogel”,The Journal of Retinal and Vitreous Diseases. vol. 19 No. 2, pp. 148-157.
D'Hermies, F. et al., “Miragel Versus Silastic Used As Episcleral Implants in Rabbits”,Retinavol. 15 No. 1 pp. 62-67 (1995).
Spitznas, M. et al., “Retinal Surgery Using Cyanoacrylate as a Routine Procedure”,Arch. Klin. exp. Ophtal. vol. 187, pp. 89-101 (1973).
Calabria, G. et al., “Sutureless Scleral Buckling”,Arch Ophtal. vol. 83, pp. 613-618 (1970).
Calabria, G. et al., “Further Experience With Sutureless Scleral Buckling Materials”,Arch Ophthal. vol. 86, pp. 82-87 (1971).
Olsen, T.W. et al., “An Evaluation of an Episcleral A
Carvalho Ricardo Azevedo Pontes de
Murphree Alan Linn
Schmitt Edward E.
Kennedy Sharon E.
Schein, Esq. Daniel B.
LandOfFree
Implantable and sealable system for unidirectional delivery... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Implantable and sealable system for unidirectional delivery..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Implantable and sealable system for unidirectional delivery... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3725390